Newest first

New topics page 16

Topics ordered by when they were created rather than by activity. This is where a question that nobody has answered yet is easiest to find — and answering one is the fastest route to a first solution badge.

1,535 topics · page 16 of 40

Topic	Participants	Replies	Views	Activity
What consumer-accessible tests can and cannot determine Analytics › Home & field testing documentation quality ELISA third-party testing What consumer-accessible tests can and cannot determine — that is the question, and I have not found it answered plainly anywhere I have looked. Something about consumer-accessible tests does not reconcile…		2	17k	1h
Micro-titration: a disputed topic, argued properly — one year on Practice › Dosing & titration dose reduction missed dose semaglutide Posting this under the heading it deserves: Micro-titration: a disputed topic, argued properly — one year on Everything below is what sits behind that. Reading back through what has been written here about…	+63	68	35k	1d
Completing a dose with a second syringe, and the dead-volume arithmetic Practice › Administration aseptic technique subcutaneous injection missed dose needle gauge & length Wiki Posting this under the heading it deserves: Completing a dose with a second syringe, and the dead-volume arithmetic Everything below is what sits behind that. I have read the maintained page on this and I…	+65	76	7.4k	1d
About the Storage & stability category Practice › Storage & stability storage temperature excursion cold chain Pinned Wiki Refrigeration, excursions, light exposure, freeze-thaw, beyond-use dating, and what published stability data actually covers. This post is a community wiki: any member at trust level 3 or above can edit it,…		4	57k	4mo
The 2.5 mg starting dose is not a therapeutic dose — why that matters Compounds › Tirzepatide SURPASS programme SURMOUNT programme effect size Solved The 2.5 mg starting dose is not a therapeutic dose — why that matters Writing it up because I had to work it out twice and would rather nobody else did. A follow-up question about 2.5 mg starting dose that I…	+119	136	5.6k	2mo
Revisiting: What SELECT changed about how semaglutide is discussed, and what it did not Compounds › Semaglutide semaglutide effect size STEP programme randomised trial Solved Revisiting: What SELECT changed about how semaglutide is discussed, and what it did not Writing it up because I had to work it out twice and would rather nobody else did. I was wrong about SELECT in a thread…		2	1.9k	5mo
Splitting an overlong document into two Documentation › Wiki requests promoted to docs review date wiki post Posting this under the heading it deserves: Splitting an overlong document into two Everything below is what sits behind that. Trying to work out what would count as evidence on splitting an overlong…	+30	34	6.2k	1d
[2026 update] Confounding by indication, explained with a concrete example Evidence › Study critique observational data disputed risk of bias Confounding by indication, explained with a concrete example Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURPASS-4 ( Lancet , 2021) cited in support of a…	+103	116	22k	5mo
Why catalogue breadth is not evidence of anything Compounds › Other compounds research use only needs a source custom synthesis Under review Why catalogue breadth is not evidence of anything I have a specific reason for asking rather than idle curiosity, and the context is below. What changes if the standard account of catalogue breadth is wrong?…		2	38k	2d
A comparison of home results against a laboratory result on the same vial — does this still hold? Analytics › Home & field testing ELISA third-party testing LOD & LOQ documentation quality Solved A comparison of home results against a laboratory result on the same vial — does this still hold? I have a specific reason for asking rather than idle curiosity, and the context is below. Comparison of home…	+2	6	15k	11h
Rotating between abdomen, thigh and upper arm: absorption differences Practice › Administration injection site reaction needle gauge & length missed dose aseptic technique On the subject in the title: Rotating between abdomen, thigh and upper arm: absorption differences Working notes rather than a conclusion. Asking about rotating between abdomen directly, because I have read…		2	3.5k	5mo
Trifluoroacetate content and its consequences Analytics › Impurities & related substances water content data table forced degradation counter-ion content Trifluoroacetate content and its consequences — setting out what I have, and where I think it stops being reliable. What changes if the standard account of trifluoroacetate content is wrong? I ask because I…	+123	134	31k	5mo
Five questions in one post gets you one answer — how to split them Start Here › How to Ask guidelines site feedback worked example Closed On the subject in the title: Five questions in one post gets you one answer — how to split them Working notes rather than a conclusion. A narrow question about five questions, deliberately narrow, because the…	+85	90	1k	2mo
Second pass at: Pregnancy and pregnancy planning: contraindication and washout Clinical › Special populations chronic kidney disease disordered eating older adults Solved Second pass at: Pregnancy and pregnancy planning: contraindication and washout Writing it up because I had to work it out twice and would rather nobody else did. Something about Pregnancy and pregnancy…	+111	127	1.6k	6mo
Bioimpedance and hydration: why the number moves Outcomes › Body composition lean mass loss data table DXA bioimpedance Bioimpedance and hydration: why the number moves — setting out what I have, and where I think it stops being reliable. I have spent a fortnight trying to pin bioimpedance and hydration down and I want to set…	+62	70	13k	23d
Reading a syringe in poor light, and how to avoid needing to — what changed since Devices › Syringes & needles dead volume subcutaneous injection syringe units needle gauge & length Posting this under the heading it deserves: Reading a syringe in poor light, and how to avoid needing to — what changed since Everything below is what sits behind that. What changes if the standard account of…	+3	7	27k	27d
Primary endpoint hierarchies and why order matters Evidence › Trials randomised trial intention to treat estimand Primary endpoint hierarchies and why order matters Writing it up because I had to work it out twice and would rather nobody else did. I was wrong about primary endpoint hierarchies in a thread last spring and…		4	308	3mo
Follow-up: The retatrutide phase 2 obesity paper, read closely Compounds › Retatrutide retatrutide randomised trial preprint effect size The retatrutide phase 2 obesity paper, read closely — setting out what I have, and where I think it stops being reliable. A follow-up question about retatrutide phase 2 obesity paper that I did not know to…	+19	23	16k	2d
Coming back to: Reading a supplier's product description as a marketing document Compounds › Other compounds needs a source custom synthesis research use only mislabelling Reading a supplier's product description as a marketing document Writing it up because I had to work it out twice and would rather nobody else did. Documentation question rather than a pharmacological one,…	+35	39	688	5mo
Residual solvents and scavengers: what is looked for — what changed since Analytics › Impurities & related substances forced degradation water content data table HPLC Solved Residual solvents and scavengers: what is looked for — what changed since — setting out what I have, and where I think it stops being reliable. What changes if the standard account of Residual solvents and…	+37	41	7k	2mo
Charge states for a 4 kDa peptide, worked through — the long version Analytics › Mass spectrometry LC-MS high-resolution MS mass error (ppm) Charge states for a 4 kDa peptide, worked through — the long version Writing it up because I had to work it out twice and would rather nobody else did. Working through the identity arithmetic and I would like…		2	293	3mo
Stability of BPC-157 in solution: what has been measured — one year on Compounds › Repair & healing peptides needs a source observational data preprint BPC-157 On the subject in the title: Stability of BPC-157 in solution: what has been measured — one year on Working notes rather than a conclusion. A narrow question about Stability of BPC-157, deliberately narrow,…	+84	98	7.8k	18h
Anaesthesia and elective surgery: the aspiration question Practice › Interactions metformin insulin delayed gastric emptying hypoglycaemia Posting this under the heading it deserves: Anaesthesia and elective surgery: the aspiration question Everything below is what sits behind that. A narrow question about anaesthesia and elective surgery,…	+103	115	6.6k	3mo
Distinguishing a red flag from an inconvenience Sourcing › Red flags mislabelling documentation quality moderation underdosing Solved Distinguishing a red flag from an inconvenience — setting out what I have, and where I think it stops being reliable. Something about distinguishing a red flag does not reconcile and I would like a second…		2	38k	6mo
Blinding yourself: practical methods and their limits Research Methods › N-of-1 designs confounding data table effect size On the subject in the title: Blinding yourself: practical methods and their limits Working notes rather than a conclusion. A methods question rather than a substantive one, about blinding yourself. Everyone…	+40	44	33k	5d
Follow-up: Lyophilisation and why the cake looks the way it does Pharmacology › Formulation chemistry bacteriostatic water cloudy or discoloured solution sterile water Solved Lyophilisation and why the cake looks the way it does Writing it up because I had to work it out twice and would rather nobody else did. I was wrong about Lyophilisation in a thread last spring and I would…	+10	14	11k	3mo
Reporting a good result: why nobody bothers and why they should Sourcing › Vendor reports third-party testing Janoshik Analytical certificate of analysis batch & lot numbers Reporting a good result: why nobody bothers and why they should — setting out what I have, and where I think it stops being reliable. Reporting a good result: setting out the arithmetic in full, because I…		2	3.5k	17h
Comparing my trajectory with the trial curves, carefully — a second dataset Outcomes › Progress reports effect size data table long read Comparing my trajectory with the trial curves, carefully — a second dataset — setting out what I have, and where I think it stops being reliable. Maintenance rather than loss, which is the part of this that…	+77	81	16k	11h
[2026 update] Area percent versus weight percent: the confusion that causes most arguments Analytics › HPLC & UHPLC gradient method UV & DAD detection peak integration data table On the subject in the title: Area percent versus weight percent: the confusion that causes most arguments Working notes rather than a conclusion. Proposing that Area percent versus weight percent deserves a…	+65	70	1.1k	16d
Manufacturer assistance programmes and their eligibility rules Access › Pricing formulary data table compounding On the subject in the title: Manufacturer assistance programmes and their eligibility rules Working notes rather than a conclusion. I have spent a fortnight trying to pin manufacturer assistance programmes…	+37	42	32k	11d